miR-1306–3p targets FBXL5 to promote metastasis of hepatocellular carcinoma through suppressing snail degradation
Highlights: • miR-1306–3p may be potential biomarker for the clinical prognosis of HCC. • miR-1306–3p may be effective target for the treatment of HCC. • miR-1306–3p regulates Snail-mediated metastasis through targeting FBXL5. • miR-1306–3p is transcripted by FOXM1 to promote HCC progression. This study aimed to elucidate the effect of miR-1306–3p on metastasis of hepatocellular carcinoma (HCC) and potential mechanism involved. miR-1306–3p promoted migration and invasion of HCC in vivo and in vitro. Moreover, miR-1306–3p inhibited snail to enhance its expression via directly targeting FBXL5, thus inducing the epithelial-mesenchymal transition (EMT) in HCC. Intriguingly, miR-1306–3p expression was transcriptionally enhanced by FoxM1. Consistently, miR-1306–3p was upregulated in HCC compared with paracarcinoma and correlated with poor prognosis of HCC patients. Our researches suggest that miR-1306–3p is a tumor enhancer in regulating of HCC metastasis, and miR-1306–3p may be clinically utilized as a factor for the clinical diagnosis and prognosis of HCC.